Droxinostat, a Histone Deacetylase Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cell Lines via Activation of the Mitochondrial Pathway and Downregulation of FLIP  by Liu, Jing et al.
www.transonc.com
Trans la t iona l Onco logy Volume 9 Number 1 February 2016 pp. 70–78 70Droxinostat, a Histone
Deacetylase Inhibitor, Induces
Apoptosis in Hepatocellular
Carcinoma Cell Lines via
Activation of the Mitochondrial
Pathway and Downregulation of
FLIP1Jing Liu*,†, Guangming Li*, Xiang Wang*,
Liang Wang*, Rui Zhao*, Juanxia Wang*,
Yin Kong*, Jie Ding*, Juan Li* and Lingyi Zhang*
*Division of Liver Disease, Lanzhou University Second
Hospital, Lanzhou, Gansu, China; †Department of
Gastroenterology, The First People's Hospital of XianYang
City, XianYang, Shaanxi, ChinaAbstract
Background: The current chemotherapeutic outcomes for hepatocellular carcinoma (HCC) are not encouraging,
and long-term survival of this patient group remains poor. Recent studies have demonstrated the utility of histone
deacetylase inhibitors that can disrupt cell proliferation and survival in HCC management. However, the effects of
droxinostat, a type of histone deacetylase inhibitor, on HCC remain to be established. Methods: The effects of
droxinostat on HCC cell lines SMMC-7721 and HepG2 were investigated. Histone acetylation and apoptosis-
modulating proteins were assessed via Western blot. Proliferation was examined with 3-(4, 5 dimetyl-2-thiazolyl)-2,
5-diphenyl 2H-tetrazolium bromide, cell proliferation, and real-time cell viability assays, and apoptosis with flow
cytometry. Results: Droxinostat inhibited proliferation and colony formation of the HCC cell lines examined.
Hepatoma cell death was induced through activation of the mitochondrial apoptotic pathway and downregulation
of FLIP expression. Droxinostat suppressed histone deacetylase (HDAC) 3 expression and promoted acetylation of
histones H3 and H4. Knockdown of HDAC3 induced hepatoma cell apoptosis and histone H3 and H4 acetylation.
Conclusions: Droxinostat suppresses HDAC3 expression and induces histone acetylation and HCC cell death
through activation of the mitochondrial apoptotic pathway and downregulation of FLIP, supporting its potential
application in the treatment of HCC.
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Hepatocellular carcinoma (HCC) is the fifth most common
malignancy and constitutes a third of cancer-related mortalities
worldwide [1]. Records have shown almost 522,000 new HCC cases
in men, 226,000 in women, and an estimated 696,000 deaths in
2008 [2]. Although surgical treatment and liver transplantation are
considered two major therapeutic options, these procedures are only
viable for about 20% of HCC cases. Surgical treatment is not feasible
in 80% patients because of diagnosis at advanced stages [3].
Intraarterial (IA) therapy, including transarterial chemoembolization,
is the validated treatment for unresectable HCC, and combining IA
with systemic targeted therapies may provide a more efficient strategy
in the future [4]. In addition to surgery and IA, chemotherapy is
another form of systemic treatment often used at advanced stages of
HCC [5]. To date, the outcomes of chemotherapy for HCC have not
been encouraging, and long-term survival of HCC patients remainspoor [4,5]. Therefore, the development of novel effective treatment
strategies for HCC is an urgent medical necessity.
Histone acetylation status is a result of the balance between the
activities of histone deacetylases (HDACs) and histone acetyl
transferases (HATs) under normal conditions. Overexpression of
HDACs and downregulation of HATs can disrupt this balance, and
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tion lead to tumors, including HCC formation and progression [6].
Kim et al. [7] reported that sustained suppression of HDAC2
attenuates colony formation in the Hep3B cell line in vitro and tumor
growth in a mouse xenograft model in vivo. The group of Zheng
demonstrated that HDAC3 plays a crucial role in regulating HCC
cell proliferation and invasion, suggesting its utility as a candidate
biomarker for predicting the prognosis of HCC following liver
transplantation [8]. Investigation of the association between HDAC
aberrations and HCC led to the hypothesis that HDACs play
important roles in regulation of the expression of signaling molecules,
constituting novel targets for anticancer drug development. Histone
deacetylase inhibitors (HDACIs) interfere with cell proliferation and
survival and are therefore feasible for treatment of HCC. Tesoriere
et al. [9] reported suberoylanilide hydroxamic acid (SAHA)-sensitive
human HCC cells at subtoxic doses to Tumor necrosis factor
(TNF)-Related Apoptosis-Inducing Ligand (TRAIL)-induced apoptosis,
compared with primary human hepatocytes. Experiments byWang et al.
[10] showed that sodium butyrate inhibits HCCmigration and invasion
by inhibiting HDAC4 and matrix metalloproteinase 7 expression.
Droxinostat (4-(4-chloro-2-methylphenoxy)-N-hydroxybutanamide),
an HDACI, was initially identified by Schimmer et al. [11]. The group
demonstrated that droxinostat sensitizes PPC-1 cells to FAS and TRAIL
via downregulating the expression of c-Fas–associated death domain-like
interleukin-1–converting enzyme-like inhibitory protein (c-FLIP) to
induce apoptosis [12]. Another study by this group demonstrated that
droxinostat sensitizes other cancer cell lines, including PC-3, T47D,
DU-145, and OVCAR-3, to anoikis or CH-11–induced apoptosis [11].
Subsequently, these researchers reported that droxinostat selectively
suppresses HDAC3, 6, and 8 and promotes histone acetylation [13].
Although droxinostat has been identified as a selective HDACI, its effects
on HCC are yet to be established.
In this study, we investigated the effects of droxinostat on human
HCC cell lines HepG2 and SMMC-7721 and its underlying
mechanisms of action. In particular, the effects of the drug on cell
proliferation, apoptosis, and expression of genes or proteins associated
with apoptosis pathways were examined. Our results clearly support
the potential application of droxinostat as an effective chemothera-
peutic agent for HCC.
Materials and Methods
Drugs and Cell Culture
Droxinostat (catalog no: S1422 USA) was purchased from Selleck
Chemicals, USA. Human liver carcinoma cell lines (SMMC-7721
and HepG2) were obtained from the State Key Laboratory of
Diagnostic and Treatment of Infectious Diseases, First Affiliated
Hospital, Zhejiang University. Cells were cultured in Dulbecco’s
modified Eagle medium (Gibco, Grand Island, NY) supplemented
with 10% (v/v) fetal bovine serum (Gibco), and incubated at 37°C in
a humidified incubator containing 5% CO2.
Real-Time Cell Viability Analysis
The xCELLLigence RTCA RT-CES SP system (Real-time
Cell-based Electronic Sensor) (Biosciences, San Diego, CA) was
used for real-time and time-dependent analysis of the cell index (CI)
of SMMC-7721 and HepG2 cells treated with different concentra-
tions of droxinostat. Each well in the 96X E-Plate (Biosciences) was
filled with 150 μl of medium. The plate was placed into thexCELLLigence Station and linked to the RECA HT Analyzer. Before
replacing the 96X E-Plate, cells were allowed to sediment
homogeneously for 30 minutes. HepG2 cells were seeded in
96-well plates at an initial density of 3 × 103 cells/well, and
SMMC-7721 cells were seeded at an initial density of 4 × 103 cells/
well. After ~24 hours, cells were washed with PBS and incubated in
complete growth medium with different concentrations (0, 10, 20,
40, and 80 μM) of droxinostat. The control group was treated with
0.9% sodium chloride. The impedance signal was expressed as CI,
indicating attachment and adherence of cells to the electrode of the
plate, and measured continuously for 96 hours.
Cell Proliferation Assay
HepG2 cells were seeded in 96-well plates at an initial density of 3 ×
103 cells/well, and SMMC-7721 cells were seeded at an initial density of
4 × 103 cells/well. After overnight growth, cells were treated with different
concentrations of droxinostat (0, 10, 20, 40, and 80 μM) for 0, 24, 48,
72, 96, and 120 hours. Serum-free Dulbecco’s modified Eagle medium
was used as the blank control, and the same density of cells as the negative
control group. After treatment, 20 μl of 5 mg/ml of 3-(4, 5
dimetyl-2-thiazolyl)-2, 5-diphenyl 2H-tetrazolium bromide (MTT) was
added to each well. Plates were incubated for a further 4 hours at 37°C,
and 150 μl of DMSO (Sigma, USA) was added to each well after
removing the supernatant. After incubation for another 10 minutes, cell
viability was assessed via measuring absorbance at 490 nm with iMark
Reader (Bio-Rad,Hercules, CA). Cell viability is indirectly represented by
absorbance values.
Colony Formation Assay
HepG2 and SMMC-7721 cells were seeded into 10-cmdishes at a very
low density of 1000 cells/dish and incubated overnight. Cells were treated
with 20 μM droxinostat or vehicle (DMSO) for 48 hours, subsequently
replaced with fresh complete medium containing drug, and incubated for
an additional 15 days in a humidified incubator at 37°C with 5% CO2.
Cell colonies were fixedwithmethanol, stainedwith crystal violet, washed
several times, and air-dried. Blue colonies were counted to indirectly
estimate cell survival.
Flow Cytometric Analysis of Apoptosis
Cells were grown in 6-well plates (HepG2 cells: 2 × 105 cell/well,
SMMC-7721 cells: 4 × 105cell/well) after 24 hours of incubation
with 0.01% DMSO or 0 to 80 μM droxinostat, and further
incubated for 48 hours. Cells were harvested, rinsed with PBS,
resuspended with 100 μl of Annexin V binding buffer, and stained
with 5 μl of Annexin V-FITC and 5 μl propidium idoide (PI) for 15
minutes in the dark. After the addition of 400 μl of AnnexinV
binding buffer, cells were analyzed via flow cytometry (BD
Bioscience, USA). Analysis was performed on FACSCalibur using
CELL Quest software. Annexin V(+)/PI(−) stained cells represent
early apoptotic cells, wheras Annexin V(+)/PI(+) staining indicates
late apoptotic cells.
Quantitative Real-Time Reverse Transcription Polymerase
Chain Reaction (q RT-PCR)
Total RNA was extracted from control and from 20-μM and
40-μM droxinostat–treated HCC cell lines using RNAiso Plus
(TaKaRa, Japan) according to the manufacturer’s instructions. RNA
was measured based on absorbance values at 260 and 280 nm to
determine concentration and purity for further use. cDNA synthesis
Table 2. Antibody Information
Antibody Company Dilution
P53 Cell Signaling, Danvers, MA 1:2000
Phospho-p53 Cell Signaling 1:2000
Bcl-2 Life Technologies 1:3000
Bax Life Technologies 1:3000
Caspase 3 Cell Signaling 1:1000
Cleaved caspase 3 Cell Signaling 1:1000
Cleaved PARP Cell Signaling 1:2000
FLIP Cell Signaling 1:1000
Caspase 8 Cell Signaling 1:1000
HDAC3 Cell Signaling 1:1000
Histone H3 Cell Signaling 1:10,000
Ac-Histone H3 Santa Cruz Biotechnology, Santa Cruz, CA, USA 1:10,000
Ac-Histone H4 Santa Cruz Biotechnology 1:10,000
β-actin Dawen Biotech, Hang Zhou, China 1:2500
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RNA, in keeping with the manufacturer’s instructions.
For real-time PCR analysis, 10 μl of cDNA template was amplified
using Power SYBR Green (ABI, USA) in an ABI 7900 HT Fast
Real-Time PCR System with the primers specified in Table 1. All
reactions were performed at least three times. For each amplification
reaction, we assessed the linear range of the standard curve obtained
from serial dilutions. Results were quantitatively calculated with the
2−ΔΔCt method. Relative quantification of target gene expression was
performed after normalization with the endogenous β-actin control.
Western Blotting
Cells were grown to 70% confluency and treated with 0, 10, 20, or 40
μM droxinostat for 48 hours before harvest. Medium and cells were
collected via centrifugation at 800g for 5 minutes and washed with cold
PBS. Total protein extraction was carried out with RIPA buffer
(Beyotime, Jiangsu, China) and nuclear protein extraction with
NE-PER Nuclear and cytoplasmic extraction reagents (Thermo, USA)
with 100mMPMSF, 10%PhosStop, and completeULTRAmini tablets
(Maibio, China) for 15 minutes on ice. Cell extracts were collected and
centrifuged at 14,000g for 20 minutes at 4°C. Supernatant fractions were
collected, and protein concentrations were determined using the Pierce
BCA Protein assay kit (Thermo Fisher Scientific Inc, Rockford, IL).
Proteins were used immediately or stored at −80°C. Protein samples were
mixed with 6× loading buffer (5:1) (Bio-Rad, Hercules, CA) and heated
in a PCR instrument at 95°C for 10 minutes. Equivalent amounts of
protein (30 μg) were separated using SDS-PAGE and transferred to
polyvinylidene difluoridemembranes (Millipore, Billerica,MA) at 300mA
in an ice bath for 45 minutes to 2 hours. Protein bands were determined
using Precision Plus protein standards (Bio-Rad, USA). Membranes were
blocked inTBST containing 1%BSA for 2 hours at room temperature and
incubated with primary antibodies including polyclonal anti-P53 et al.
(shown in Table 2) at 4°C overnight on a shaking bed, respectively.
Membranes were washed three times with 1× TBST and incubated with
secondary HRP-conjugated anti-mouse or anti-rabbit IgG (Dawen
Bioscience, China) for 1 hour at room temperature. After washing three
times, blots were visualized and detected with ECL (Minipore, Germany)
following exposure to X-ray film in the dark room.
RNA Interference
Small interfering RNA for HDAC3 (si-HDAC3) (catalog no:
sc35538) and nonspecific siRNA (si-Control) were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). HepG2 and
SMMC-7721 cells were seeded at concentrations of 2 × 105/well in
6-well plates and grown overnight. Cells in each well were transfected
with 100 nM siRNA using Lipofectamine RNAi MAX Reagent
(Invitrogen, CA) according to the manufacturer’s protocol. After 48Table 1. List of Primers Used for q RT-PCR
Gene Generic Primers
p53 F 5′-CCTCAGCATCTTATCCGAGTG-3′
R 5′-TCATAGGGCACCACCACAC-3′
Bcl-2 F 5′-ATGTGTGTGGAGAGCGTCAA-3′
R 5′-GAGACAGCCAGGAGAAATCAA-3′
Bax F 5′-GGGTTGTCGCCCTTTTCTAC-3′
R 5′-TGAGGAGGCTTGAGGAGTCT-3′
β-actin F 5′-GTGGCCGAGGACTTTGATTG-3′
R 5′-AGTGGGGTGGCTTTTAGGATG-3′
Abbreviations: F, forward primer; R, reverse primer.hours of transfection, cells were employed for gene knockdown, flow
cytometric analysis of apoptosis, and Western blot.
Statistical Analysis
Results are expressed as mean ± standard error (SE) from at least
three independent experiments. Differences between groups were
examined for statistical significance using one-way analysis of
variance. All P values are two-sided, and values b .05 were considered
statistically significant (denoted *).
Results
Droxinostat Inhibits Cell Proliferation of HCC Cell Lines
To determine the effects of droxinostat on HCC cell proliferation,
two human hepatoma cell lines (HepG2 and SMMC-7721) were
analyzed using the MTT assay and the RTCA RT-CES SP system.
We observed a time- and dose-dependent decrease in viability in both
cell lines cultured in the presence of micromolar concentrations of
droxinostat for 120 hours in the MTT assay and 96 hours in the
RT-CES SP system (Figure 1, A, B, D, and E). A concentration of 10
μM droxinostat had no effect on the 2 cell lines in the MTT assay
(Figure 1, A and D), whereas these cell lines displayed sensitivity to
the agent of 10 μM with the RT-CES SP system (Figure 1, B and E).
Accordingly, the drug concentration used for inhibiting colony
formation was selected as 20 μM. The numbers of colonies formed in
the drug-treated groups, compared with their control counterparts,
are depicted in Figure 1, C and F.
Droxinostat Suppresses HDAC3 Expression and Induces
Acetylation of Histones H3 and H4
Previous studies by Zhou et al. indicate a crucial role of HDAC3 in
regulating HCC cell proliferation and invasion [8]. Droxinostat acts as a
selective inhibitor of HDACs [13]. To ascertain whether droxinostat
suppresses HDAC3 expression in HCC, HepG2 and SMMC-7721 cells
were incubated with the drug for 48 hours, and HDAC3 levels were
analyzed viaWestern blot. Significantly lower expression of HDAC3 was
evident in both cell lines treated with droxinostat (Figure 2, A–E).
Furthermore, our experiments revealed dose-dependent downregulation
of HDAC3, compared with the control groups, in HepG2 and
SMMC-7721 cell lines (Figure 2, B and F). To determine whether
inhibition of HDAC3 induces histone acetylation, lysates obtained from
droxinostat-treated cells were examined. Droxinostat significantly
enhanced the expression of acetyl-H3 (Ac-H3) and acetyl-H4 (Ac-H4)
inHepG2 and SMMC-7721 cells in a dose-dependentmanner, as shown
in Figure 2, C, G, D, and H.
Figure 1. Droxinostat inhibits cell proliferation and colony formation in HepG2 and SMMC-7721 cells. (A, D) MTT assay illustrating cell
proliferation (0 to 120 hours) following treatment with various concentrations of droxinostat in HepG2 (A) and SMMC-7721 (D) cells. Data
are expressed as absorbance values (490 nm), compared with untreated control cells. (B, E) The Real-time cell viability analysis ( RTCA
RT-CES SP) system, another cell proliferation method, shown the following 96-hour treatment with various concentrations of droxinostat
added at 24 hours in HepG2 (b) and SMMC-7721 (E) cells. Data are expressed as CI, compared with untreated control cells. (C, F) Number
of colonies in HepG2 (C) and SMMC-7721 (F) cells after treatment with 20 μMdroxinostat at 15 days. Results are expressed as number of
colonies, compared with the control group (mean ± SE) (*P b .05, **P b .01).
Figure 2. Droxinostat suppresses HDAC3 expression and acetylates histones H3 and H4. HepG2 (A) and SMMC-7721(B) cells were
cultured with 0, 10, 20, or 40 μM droxinostat for 48 hours. Western blot analysis using antibodies against HDAC3, Ac-H3, and Ac-H4 was
performed after 48-hour incubation with droxinostat. Internal reference protein loading was verified via the detection of β-actin. (B, D, F, H)
Protein expression, expressed as relative content, was examined using Gray analysis and compared with that in the control group (mean
± SE) (*P b .05, **P b .01).
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Figure 3. Droxinostat induces HepG2 cell apoptosis by activating themitochondrial apoptotic pathway and downregulating expression of FLIP. (A)
Apoptotic cells were determined via flow cytometry following staining with Annexin V and PI. (B) Apoptosis rates of HepG2 cells treated with
different concentrations of droxinostat were analyzed using bar graphs. (C) mRNA levels of genes related to the mitochondrial p53 apoptosis
pathwaywere analyzed using qRT-PCR. (D) Levels of proteins associatedwith themitochondrial p53 apoptosis pathwaywere analyzed viaWestern
blot. (E) The relative contents of proteins of themitochondrial p53 apoptosis pathwaywere analyzed using bar graphs. (F) Bax/Bcl-2 protein ratio. (G)
Protein levels related to FLIP and caspase-8were analyzed viaWestern blot. (H) Relative FLIP and caspase-8 levelswere analyzed using bar graphs.
Data are shown as means ± SE of three independent experiments, *P b .05, **P b .01, compared with untreated control cells (no droxinostat).
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We examined the apoptotic status of HepG2 and SMMC-7721 cells
incubatedwithdifferent concentrations of droxinostat after 48hours via flowcytometry.Droxinostat treatment ofHepG2 (Figure 3A) and SMMC-7721
cells (Figure 4A) clearly led to dose-dependent apoptosis. Notably, 10 μM
droxinostat did not induce hepatoma cell apoptosis, whereas a starting
concentration of 20 μM had an apoptotic effect (Figures 3B and 4B).
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diated HCC cell apoptosis, expression patterns of key proteins related
to apoptotic signaling pathways were explored via qRT-PCR and
Western blot analyses. As shown in Figures 3C and 4C, mRNA levels
of Bax and p53 genes associated with the mitochondrial p53 apoptosis
pathway were significantly increased in HepG2 and SMMC-7721
cells treated with droxinostat in a dose-dependent manner. Although
Bcl-2 mRNA levels were significantly increased in SMMC-7721 cells
at a treatment concentration of 40 μM, the Bax/Bcl-2 mRNA ratio
was also increased. Expression levels of proteins related to the
mitochondrial p53 apoptosis pathway were additionally analyzed via
Western blot (Figures 3D and 4D). Evident upregulation of
phospho-p53 and cleaved caspase 3 protein and downregulation of
Bcl-2 suggested a role of the mitochondrial p53 pathway in
droxinostat-mediated apoptosis (Figures 3E and 4E). Interestingly,
although Bax, a critical factor in inducing apoptosis, was not
significantly increased, the Bax/Bcl-2 ratio was markedly increased
upon treatment in a dose-dependent manner (Figures 3F and 4F). In
HepG2 cells, expression of cleaved PARP protein was increased in a
dose-dependent manner (Figures 3D and 4E). However, this result
was not observed in SMMC-7721 cells.
To further clarify whether FLIP participates in droxinostat-mediated
HCC cell apoptosis, we examined changes in FLIP and caspase 8 protein
expression via Western blot. Strikingly, both HepG2 (Figure 3G) and
SMMC-7721 (Figure 4G) cell groups displayed a significant reduction in
FLIP expression and enhanced caspase 8 activity.
Our experiments collectively suggest that the ability of droxinostat
to induce hepatoma cell apoptosis is attributable to activation of the
mitochondrial apoptotic pathway and reduction of FLIP.
Knockdown of HDAC3 Induces Hepatoma Cell Apoptosis and
Acetylation of Histones H3 and H4
Droxinostat has been shown to suppress HDAC3 expression and
induce hepatoma cell apoptosis. To determine the potential link
between droxinostat-mediated suppression of HDAC3 and its effects
on hepatoma cell apoptosis, HDAC3 expression in hepatoma cells
was silenced and the effects examined.
As shown in Figure 5C, Western blot analysis revealed a significant
decrease inHDAC3 expression inHepG2 cells upon siRNA transfection.
Moreover, the apoptotic rate was significantly increased in HDAC3
siRNA than control siRNA and reagent-treated groups (Figure 5, A and
B), and expression of cleaved PARP and caspase 3 proteins was
upregulated (Figure 5,D and E). Simultaneously, transfection of HepG2
with HDAC3 siRNA induced a significant increase in expression of
Ac-H3 and Ac-H4 proteins (Figure 5, G and H).
In both HepG2 and SMMC-7721 cell lines, silencing of HDAC3
led to a marked increase in cellular apoptosis (Figure 5, H and I),
expression of cleaved caspase 3 (Figure 5, K and L), and acetylated
histones (Figure 5, M and N).
Discussion
HCC is one of the most common progressive malignancies associated
with significant mortality worldwide. Although surgical treatment and
liver transplantation are considered two major efficacious therapeutic
options for early disease, prognosis for patients with HCC remains very
poor owing to frequent diagnosis at advanced stages. Outcomes of
chemotherapy for HCC are not encouraging, and long-term survival of
these patients is poor [3]. Droxinostat has been reported to sensitize
cancer cell lines, including PPC-1, PC-3, T47D, DU-145, andOVCAR-3, to apoptosis [11]. Data from the current study showed
that droxinostat inhibits proliferation of the hepatocellular cell lines
SMMC-7721 and HepG2 and colony formation in vitro.
Induction of cellular apoptosis is one of the key mechanisms of
action of anticancer drugs. In our experiments, droxinostat inhibited
HCC growth and induced apoptosis. Droxinosat has been shown to
induce apoptosis in prostate cancer and breast cancer cells via
downregulating c-FLIP [12]. Here, we showed that induction of
apoptosis by droxinostat is mediated through modulation of proteins
of the mitochondrial pathway and expression of FLIP in the HCC cell
lines HepG2 and SMMC-7721.
HDACIs induce tumor apoptosis via the intrinsic/mitochondrial and
death receptor (DR)/extrinsic pathways [14]. The mitochondrion is an
important participant in apoptosis following exposure to various death
stimuli, including UV- and γ-irradiation, hypoxia, hyperthermia,
chemotherapeutic drugs, viral infections, and free radicals [15,16]. The
mitochondrial pathway is regulated by pro- and antiapoptotic Bcl-2
multidomain family members [17]. Antiapoptotic Bcl-2 proteins (Bcl-2,
Bcl-XL, Bcl-w) maintain the integrity of the mitochondrial membrane
[18]. Proapoptotic Bcl-2 proteins (Bax, Bak, Bim, Bad, Bid, Bik, Bmf) are
necessary for the onset of mitochondrial dysfunction and cell death
following diverse signals [19]. Once the pro/antiapoptotic balance is
disrupted, proapoptotic Bcl-2 proteins activate cytochrome c and second
mitochondria derived activator of caspase release from the intermembrane
space. Cytochrome c triggers a postmitochondrial pathway, forming an
“apoptosome” of cytochrome c, Apaf-1, and caspase-9, in turn activating
caspase-9, which subsequently cleaves the downstream effectors
caspases-3 and -7 [20].
HDACIs enhance extrinsic apoptosis signaling through diverse
mechanisms, including upregulation of TRAIL (it also known as
Apo2L, TNFS10) [9,21,22], and DR [9,21], and reduction in the
c-FLIP level [21]. The DR/extrinsic apoptosis pathway is activated by
binding of TRAIL/Apo2L and TNF-α to TRAIL-R1 (DR-4) or
TRAIL-R2 (DR-5) in human cells [14,9,21,22]. Formation of the
death-inducing signaling complex ultimately results in initiation of
apoptosis via cleavage of caspase-8/10, and activation of downstream
caspases-3 and -7 [20]. In addition to activation of the mitochondrial
pathway by death stimuli, DRs activate the mitochondrial pathway
through caspase 8–mediated cleavage and activation of Bid. In this
way, Bid serves as a molecular link between the two pathways [23].
HDACIs have been shown to induce HCC cell apoptosis [24–26].
Moreover, a number of studies have demonstrated apoptosis induction
with a combination of HDACIs and other antitumor drugs [27,28].
Here, we have shown that droxinostat, an effective inhibitor of
HDACs, sensitizes human HCC cell lines (HepG2 and
SMMC-7721) to induce apoptosis. Previously, droxinostat was
identified as a selective HDACI that can induce anoikis or CH-11–
induced apoptosis in cancer cell lines, including PC-3, T47D,
DU-145, and OVCAR-3 [12]. The effects of droxinostat on HCC
have not been established to date. Our experiments initially
demonstrated that droxinostat inhibits hepatoma cell proliferation
and induces cell apoptosis. To elucidate the potential mechanisms
underlying cell apoptosis, we examined the effects of the compound
on expression of mitochondrial pathway proteins and FLIP in HepG2
and SMMC-7721 cell lines. Droxinostat induced dose-dependent
significant downregulation of Bcl-2 protein, upregulation of Bax, and
enhanced Bax/Bcl-2 ratio. These findings support the activation of an
intrinsic apoptotic pathway by droxinostat in the HCC cell lines.
Moreover, low doses of droxinostat suppressed the level of FLIP and
Figure 4.Droxinostat induces apoptosis in SMMC-7721 cells by activating themitochondrial apoptotic pathway and downregulating FLIP.
(A) Apoptotic cells were determined via flow cytometry following staining with Annexin V and PI. (B) Apoptosis rates of SMMC-7721 cells
treated with different concentrations of droxinostat were analyzed using bar graphs. (C) mRNA levels of genes related to the
mitochondrial p53 apoptosis pathway were analyzed using qRT- PCR. (D) Levels of proteins associated with the mitochondrial p53
apoptosis pathway were analyzed via Western blot. (E) Relative contents of proteins from the mitochondrial p53 apoptosis pathway were
analyzed using bar graphs. (F) Bax /Bcl-2 protein ratio. (G) Protein levels of FLIP and caspase-8 were analyzed via Western blot. (H) Relative
contents of FLIP and caspase-8 were analyzed using bar graphs. Data are presented as means ± SE of three independent experiments,
*P b .05, **P b .001, compared with untreated control cells (no droxinostat).
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Figure 5. Knockdown of HDAC3 induces hepatoma cell apoptosis and acetylation of histones H3 and H4. A: Data obtained with HepG2
cells. (A) Apoptotic populations of HepG2 HDAC3-silenced cells determined via flow cytometry. (B) Analysis of apoptosis rates using bar
graphs. (C) HDAC3 protein is downregulated by siRNA against HDAC3 in HepG2 cells. (D, E) Expression of cleaved PARP and cleaved
caspase 3 proteins is significantly increased upon knockdown of HDAC3 in HepG2 cells. (F, G) Expression of Ace-H3 and Ace-H4 proteins
is significantly increased upon knockdown of HDAC3 in HepG2 cells. B: Data obtained with SMMC-7721 cells. (H) Apoptotic population of
SMMC-7721 HDAC3-silenced cells determined via flow cytometry. (I) Analysis of apoptosis rates using bar graphs. (J) HDAC3 is
downregulated by siRNA against HDAC3 in SMMC-7721 cells. (H, L) Expression of cleaved caspase 3 is significantly increased upon
knockdown of HDAC3 in SMMC-7721 cells. (M, N) Expression of Ace-H3 and Ace-H4 proteins is significantly increased upon knockdown
of HDAC3 in SMMC-7721 cells.
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human hepatocarcinoma cells to the extrinsic apoptosis pathway
through downregulating FLIP. Meanwhile, cleaved PARP expression
was upregulated in HepG2, but not SMMC-7721 cells, indicating
the involvement of other regulation factors that requires further
investigation.
Epigenetic aberrations play a critical role in the development and
progression of human HCC [29]. Histone modification is one of the
most important types of epigenetic changes, and its status is balanced
by the activities of HDACs and HATs. Several studies have disclosed
an important role of HDAC3 in the development and progression of
HCC. Zheng et al. reported that HDAC3 is highly expressed and an
unfavorable independent prognostic factor in HCC patients.
Inhibition of HDAC3 leads to suppression of proliferation and
invasiveness of HCC cells in vitro, supporting its applicability as acandidate biomarker for predicting recurrence of HCC following liver
transplantation [8]. Meanwhile, Yang et al. showed that hypoxia
improves HDAC3 expression by affecting the level of histone
acetylation and nuclear factor-90 expression to promote HCC cell
invasion and metastasis [30].
Thus, HDAC3 is overexpressed in HCC tissues and cells.
Droxinostat, a specific HDACI, specifically inhibits HDAC3, 6,
and 8 expression. Here, we examined the hypothesis that droxinostat
mediates suppression of tumor development through inhibition of
HDAC3. Our experiments showed that droxinostat inhibits HDAC3
and promotes AceH3 and AceH4 expression. These effects may be
related to facilitation of gene transcription through increasing
acetylation levels and further relaxation of the chromosome status.
Because of acetylation of lysine residues, the positive charge at the
N-terminal tail domains of histone is decreased and interactions with
78 Droxinostat Induces Apoptosis in HCC Cell Lines Liu et al. Translational Oncology Vol. 9, No. 1, 2016DNA are weakened, allowing transcription factors to bind to DNA
and initiate transcriptional machinery [31]. To further investigate the
relationship between droxinostat-induced HCC cell apoptosis and
expression of HDAC3, we disrupted HDAC3 expression in HCC
cells. Apoptosis rates and cleaved caspase 3 levels were increased under
these conditions, supporting the theory that droxinostat induces
HCC cell apoptosis via suppression of HDAC3.
In conclusion, droxinostat induces apoptosis in HepG2 and
SMMC-7721 cells through activating the mitochondrial apoptotic
pathway and downregulating expression of FLIP. In view of the
complex pathways of apoptosis, other extrinsic apoptosis and
endoplasmic reticulum–mediated signaling pathways cannot be
overlooked and should be investigated in the future. Acetylation of
histones plays an essential role in the pathogenesis of HCC and is
dependent on the counterbalance between HDAC and HAT
activities. Our results showed that droxinostat suppresses HDAC3
expression and induces acetylation of histones H3 and H4. We
propose that inhibition of HDAC3 promotes histone acetylation,
which may be the molecular mechanism underlying the proapoptotic
function of droxinostat in HCC. The antitumor effects of droxinostat
require further research in vivo and in vitro to establish its potential as
a novel inhibitory agent for HCC.
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